Apolipoprotein C-II is a potential serum biomarker as a prognostic factor of locally advanced cervical cancer after chemoradiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 5, 2013, Pages 1155-1161

  Harima, Yoko ^a   Ikeda, Koshi ^a   Utsunomiya, Keita ^a   Komemushi, Atsushi ^a   Kanno, Shohei ^a   Shiga, Toshiko ^a   Tanigawa, Noboru ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERVICAL CARCINOMA; CHEMORADIATION THERAPIES; IDENTIFICATION METHOD; METHODS AND MATERIALS; PEPTIDE MASS FINGERPRINTING; PROGNOSTIC FACTORS; RADIATION TREATMENTS; TREATMENT OUTCOMES;

CHEMORADIOTHERAPY; DIAGNOSIS; LIPOPROTEINS; MASS SPECTROMETRY; PEPTIDES;

BODY FLUIDS;

APOLIPOPROTEIN C2; CISPLATIN; IRIDIUM 192; IRIDIUM; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; ASSAY; BRACHYTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; PEPTIDE MASS FINGERPRINTING; PRIORITY JOURNAL; SURFACE ENHANCED LASER DESORPTION AND IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; TURBIDIMETRIC ASSAY; UTERINE CERVIX CARCINOMA; BLOOD; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; MASS SPECTROMETRY; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PEPTIDE MAPPING; PHOTOMETRY; PROCEDURES; PROGNOSIS; PROTEIN MICROARRAY; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VALIDATION STUDY;

APOLIPOPROTEIN C-II; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHEMORADIOTHERAPY; FEMALE; HUMANS; IRIDIUM RADIOISOTOPES; NEPHELOMETRY AND TURBIDIMETRY; PEPTIDE MAPPING; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STATISTICS, NONPARAMETRIC; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84888289420     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.08.023     Document Type: Article

References (23)

1. M. Arbyn, X. Castellsagué, and S. de Sanjosé Worldwide burden of cervical cancer in 2008 Ann Oncol 22 2011 2675 2686
2. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: Individual patient data meta-analysis Cochrane Database Syst Rev 1 2010 CD008285
3. M.G. Noordhuis, J.H. Jasper, and E.F. Roossink Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: A systematic review Int J Radiat Oncol Biol Phys 79 2011 325 334
4. Y. Harima, K. Ikeda, and K. Utsunomiya Identification of genes associated with progression and metastasis of advanced cervical cancers after radiotherapy by cDNA microarray analysis Int J Radiat Oncol Biol Phys 75 2009 1232 1239
5. Y. Shen, J. Kim, and E.F. Strittmatter Characterization of the human blood plasma proteome Proteomics 5 2005 4034 4045
6. Y.W. Lin, C.Y. Lin, and H.C. Lai Plasma proteomic pattern as biomarkers for ovarian cancer Int J Gynecol Cancer 16 Suppl 1 2006 139 146
7. J. Guo, E.C. Yang, and L. Desouza A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma Proteomics 5 2005 1953 1966
8. J.L. Benedet, H. Bender, and H. Jones FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology Int J Gynaecol Obstet 70 2000 209 262
9. International Commission of Radiation Units and Measurements ICRU Report No. 38. Dose and volume specification for reporting intracavitary therapy in gynecology 1985 International Commission of Radiation Units and Measurements Bethesda, MD 1 16
10. Z. He, C. Yang, and W. Yu Peak bagging for peptide mass fingerprinting and tandem MS (MS/MS)-based peptide/protein identification method Bioinformatics 24 2008 1293 1299
11. F.J. Schweigert, K. Wirth, and J. Raila Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay Proteome Sci 2 2004 5
12. A. Gadducci, R. Tana, and S. Cosio The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature Crit Rev Oncol Hematol 66 2008 10 20
13. I. Ogino, H. Nakayama, and N. Okamoto The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy Int J Gynecol Cancer 16 2006 1094 1100
14. J.H. Hong, C.S. Tsai, and J.T. Chang The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy Int J Radiat Oncol Biol Phys 41 1998 823 830
15. M.C. Jong, M.H. Hofker, and L.M. Havekes Role of ApoCs in lipoprotein metabolism: Functional differences between ApoC1, ApoC2, and ApoC3 Arterioscler Thromb Vasc Biol 19 1999 472 484
16. J.C. LaRosa, R.I. Levy, and P. Herbert A specific apoprotein activator for lipoprotein lipase Biochem Biophys Res Commun 41 1970 57 62
17. J. Chen, M. Anderson, and D.E. Misek Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry J Chromoatogr A 1162 2007 117 125
18. S. Takasu, M. Mutoh, and M. Takahashi Lipoprotein lipase as a candidate target for cancer prevention/therapy Biochem Res Int 2012 2012 1 8
19. S.Y. Kim, S.M. Park, and S. Lee Apolipoprotein C-II is a novel substrate for matrix metalloproteinases Biochem Biophys Res Commun 339 2006 47 54
20. E.A. Nigg Mitotic kinases as regulators of cell division and its checkpoints Nat Rev Mol Cell Biol 2 2001 21 32
21. V.M. Stucke, H.H. Sillje, and L. Arnaud Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication EMBO J 21 2002 1723 1732
22. O. Brummer, G. Bohmer, and B. Hollwitz MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - an immunohistochemical study Gynecol Oncol 84 2002 222 227
23. P.L. Moser, D.G. Kieback, and L. Hefler Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer Anticancer Res 19 1999 4391 4393